This is particularly important because, apart from BRCA1/BRCA2 MINAS, other CSG MINAS combinations are rare and so clinicians faced with an individual with non-BRCA1/BRCA2 MINAS will often find it very difficult to predict what the implications are for tumour risks in that individual. The gene discussed is BRCA2; the disease is neoplasm.